Lionsgate, Icahn ramp up battle

Both sides campaign over 'poison pill' provision

Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision.

Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.”

Separately, Icahn’s said in a regulatory filing that the poison pill would “frustrate” the ability of Lionsgate shareholders to decide whether to accept Icahn’s offer.

The plan, to be voted on at a May 4 meeting in Toronto, would have the effect of diluting Icahn’s ownership of Lionsgate — currently at 19% — if his holdings top 20%.

Icahn, frustrated by a stagnant stock price, is attempting to buy the 81% of Lionsgate that he doesn’t own at $6 a share via a tender offer that expires April 30. Shares were up a penny to $6.20 in mid-session trading Friday.

Icahn has portrayed the poison pill as “totalitarian.” Lionsgate has repeatedly called Icahn’s offer “financially inadequate and coercive.”

The Glass Lewis report said, “In this case, although the Rights Plan does not contain qualifying offer provisions, in our view, the permitted bid provisions adequately ensure that shareholders are able to consider a reasonable offer for the company. Further, we note that the Rights Plan will expire in three years. In light of these shareholder-friendly provisions, we believe that the Rights Plan may serve to protect Shareholder interests in the event that a takeover bid does not reflect the full value of the company’s shares or is coercive.”

Icahn, in a filing Thursday with the Securities and Exchange Commission, noted that Lionsgate had never adopted a shareholder rights plan.

“The Icahn Group believes that the Poison Pill seriously prejudices the interests of Lionsgate shareholders by precluding them from exercising their fundamental right to decide whether to tender their Lionsgate shares to the Icahn Offer,” it added.

Lionsgate contended in its announcment that the plan is intended to protect Lionsgate and its shareholders from “unfair and coercive” attempts to take over the company. It also said that the plan “enables Lionsgate to continue to execute on its current plans to build shareholder value.”

Shares of Lionsgate – home to “Precious” and the Saw and Tyler Perry franchises along with “Mad Men” and “Weeds” — have been depressed partly by uneven performance of its film slate. “Tyler Perry’s Why Did I Get Married Too” has performed respectably and topped $36 million in domestic grosses in its first six days.

More Film

  • Morgan Freeman Sexual Harassment

    Morgan Freeman Issues New Statement: 'I Did Not Assault Women'

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

  • Euphoria Review

    Cannes Film Review: 'Euphoria'

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

  • David Permut

    David Permut, Naomi Kawase Join Shanghai Festival Jury

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

  • 'Adrift' Director Baltasar Kormakur on Casting

    'Adrift' Director Baltasar Kormakur on Casting Shailene Woodley, Shooting Surrounded by Sharks

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

  • Trevor Jackson and Jason Mitchell in

    Film News Roundup: Sony Opening Crime Thriller 'Superfly' Two Days Earlier

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

  • The Dead and the Others Review

    Cannes Film Review: 'The Dead and the Others'

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

  • Transilvania Film Fest Raises Curtain on

    Transilvania Film Festival Raises Curtain on 17th Edition

    Lionsgate and Carl Icahn are ramping up their battle for control of the minimajor, with both sides campaigning over Lionsgate’s proposed “poison pill” provision. Lionsgate announced Friday that independent proxy advisory firm Glass Lewis & Co had recommended that Lionsgate shareholders vote for what the company’s dubbed its “shareholder rights plan.” Separately, Icahn’s said in […]

More From Our Brands

Access exclusive content